Cargando…
A triple action CDK4/6-PI3K-BET inhibitor with augmented cancer cell cytotoxicity
| Autores principales: | , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Springer Singapore
2020
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7385619/ https://www.ncbi.nlm.nih.gov/pubmed/32793389 http://dx.doi.org/10.1038/s41421-020-0181-z |
| _version_ | 1783563823244902400 |
|---|---|
| author | Burgoyne, Adam M. Vann, Kendra R. Joshi, Shweta Morales, Guillermo A. Vega, Francisco M. Singh, Alok Pal, Dhananjaya Merati, Aran B. Kutateladze, Tatiana G. Durden, Donald L. |
| author_facet | Burgoyne, Adam M. Vann, Kendra R. Joshi, Shweta Morales, Guillermo A. Vega, Francisco M. Singh, Alok Pal, Dhananjaya Merati, Aran B. Kutateladze, Tatiana G. Durden, Donald L. |
| author_sort | Burgoyne, Adam M. |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-7385619 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2020 |
| publisher | Springer Singapore |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-73856192020-08-12 A triple action CDK4/6-PI3K-BET inhibitor with augmented cancer cell cytotoxicity Burgoyne, Adam M. Vann, Kendra R. Joshi, Shweta Morales, Guillermo A. Vega, Francisco M. Singh, Alok Pal, Dhananjaya Merati, Aran B. Kutateladze, Tatiana G. Durden, Donald L. Cell Discov Correspondence Springer Singapore 2020-07-28 /pmc/articles/PMC7385619/ /pubmed/32793389 http://dx.doi.org/10.1038/s41421-020-0181-z Text en © The Author(s) 2020 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
| spellingShingle | Correspondence Burgoyne, Adam M. Vann, Kendra R. Joshi, Shweta Morales, Guillermo A. Vega, Francisco M. Singh, Alok Pal, Dhananjaya Merati, Aran B. Kutateladze, Tatiana G. Durden, Donald L. A triple action CDK4/6-PI3K-BET inhibitor with augmented cancer cell cytotoxicity |
| title | A triple action CDK4/6-PI3K-BET inhibitor with augmented cancer cell cytotoxicity |
| title_full | A triple action CDK4/6-PI3K-BET inhibitor with augmented cancer cell cytotoxicity |
| title_fullStr | A triple action CDK4/6-PI3K-BET inhibitor with augmented cancer cell cytotoxicity |
| title_full_unstemmed | A triple action CDK4/6-PI3K-BET inhibitor with augmented cancer cell cytotoxicity |
| title_short | A triple action CDK4/6-PI3K-BET inhibitor with augmented cancer cell cytotoxicity |
| title_sort | triple action cdk4/6-pi3k-bet inhibitor with augmented cancer cell cytotoxicity |
| topic | Correspondence |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7385619/ https://www.ncbi.nlm.nih.gov/pubmed/32793389 http://dx.doi.org/10.1038/s41421-020-0181-z |
| work_keys_str_mv | AT burgoyneadamm atripleactioncdk46pi3kbetinhibitorwithaugmentedcancercellcytotoxicity AT vannkendrar atripleactioncdk46pi3kbetinhibitorwithaugmentedcancercellcytotoxicity AT joshishweta atripleactioncdk46pi3kbetinhibitorwithaugmentedcancercellcytotoxicity AT moralesguillermoa atripleactioncdk46pi3kbetinhibitorwithaugmentedcancercellcytotoxicity AT vegafranciscom atripleactioncdk46pi3kbetinhibitorwithaugmentedcancercellcytotoxicity AT singhalok atripleactioncdk46pi3kbetinhibitorwithaugmentedcancercellcytotoxicity AT paldhananjaya atripleactioncdk46pi3kbetinhibitorwithaugmentedcancercellcytotoxicity AT meratiaranb atripleactioncdk46pi3kbetinhibitorwithaugmentedcancercellcytotoxicity AT kutateladzetatianag atripleactioncdk46pi3kbetinhibitorwithaugmentedcancercellcytotoxicity AT durdendonaldl atripleactioncdk46pi3kbetinhibitorwithaugmentedcancercellcytotoxicity AT burgoyneadamm tripleactioncdk46pi3kbetinhibitorwithaugmentedcancercellcytotoxicity AT vannkendrar tripleactioncdk46pi3kbetinhibitorwithaugmentedcancercellcytotoxicity AT joshishweta tripleactioncdk46pi3kbetinhibitorwithaugmentedcancercellcytotoxicity AT moralesguillermoa tripleactioncdk46pi3kbetinhibitorwithaugmentedcancercellcytotoxicity AT vegafranciscom tripleactioncdk46pi3kbetinhibitorwithaugmentedcancercellcytotoxicity AT singhalok tripleactioncdk46pi3kbetinhibitorwithaugmentedcancercellcytotoxicity AT paldhananjaya tripleactioncdk46pi3kbetinhibitorwithaugmentedcancercellcytotoxicity AT meratiaranb tripleactioncdk46pi3kbetinhibitorwithaugmentedcancercellcytotoxicity AT kutateladzetatianag tripleactioncdk46pi3kbetinhibitorwithaugmentedcancercellcytotoxicity AT durdendonaldl tripleactioncdk46pi3kbetinhibitorwithaugmentedcancercellcytotoxicity |